Nevertheless, the majority of the promising preclinical evidence resulted in FGFR1 amplification being proposed as a predictive biomarker of FGFR inhibition in advanced Sq-NSCLC. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.